1. Home
  2. DERM vs ABOS Comparison

DERM vs ABOS Comparison

Compare DERM & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Journey Medical Corporation

DERM

Journey Medical Corporation

HOLD

Current Price

$6.35

Market Cap

190.3M

Sector

Health Care

ML Signal

HOLD

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

HOLD

Current Price

$2.28

Market Cap

197.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DERM
ABOS
Founded
2014
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
197.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DERM
ABOS
Price
$6.35
$2.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$12.67
$8.00
AVG Volume (30 Days)
165.8K
368.5K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
34.72
N/A
EPS
N/A
N/A
Revenue
$61,858,000.00
N/A
Revenue This Year
$39.72
N/A
Revenue Next Year
$63.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.20
N/A
52 Week Low
$4.31
$1.19
52 Week High
$9.56
$3.60

Technical Indicators

Market Signals
Indicator
DERM
ABOS
Relative Strength Index (RSI) 43.53 46.56
Support Level $5.80 $2.13
Resistance Level $6.59 $2.45
Average True Range (ATR) 0.36 0.15
MACD -0.12 -0.03
Stochastic Oscillator 25.52 26.53

Price Performance

Historical Comparison
DERM
ABOS

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: